Abstract
ABSTRACT The medical and pharmaceutical industries must commit to full consensus on biosimilar products. Regulatory recommendations and current resources applied to biosimilars should not be squandered. Additionally, continued lessons learned should be applied for the preparation of future unknown classes of medical treatments. Recommendations from provider consensus are sound, logical, and feasible. These should be set forth, implemented and agreed upon globally.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
